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Background: Allergen-specific immunotherapy has been demonstrated to have potential for the treatment of
allergic diseases. Transgenic animals are currently the best available bioreactors to produce recombinant proteins,
which can be secreted in milk. It has not been clearly demonstrated whether milk from transgenic animals
expressing recombinant allergens has immunomodulatory effects on allergic asthma.
Methods: We aimed to determine whether the oral administration of milk containing a mite allergen can down-
regulate allergen-specific airway inflammation. Transgenic CD-1 mice that express a recombinant group 2 allergen
from Dermatophagoides pteronyssinus (Dp2) in their milk were generated using an embryonic gene-microinjection
technique. Mouse pups were fed transgenic Dp2-containing milk or wild-type milk. Subsequently, these mice were
sensitized and challenged with Dp2 to induce allergic airway inflammation.
Results: Upon sensitization and challenge, mice fed transgenic Dp2 milk had decreased T-helper 2 (Th2) and
increased T-helper 1 (Th1) responses in the airway compared with mice fed wild-type milk. Moreover, pre-treatment
with transgenic Dp2 milk attenuated airway inflammation and decreased airway hyper-responsiveness.
Conclusions: This study provides new evidence that oral administration of transgenic milk containing the Dp2
allergen down-regulated and moderately protected against allergic airway inflammation. Milk from transgenic
animals expressing allergens may have potential use in the prevention of allergic asthma.
Keywords: Transgenic mice, Allergen, Asthma, Immunotherapy, Group 2 allergen of Dermatophagoides
pteronyssinus, ToleranceBackground
Allergic asthma is an inflammatory airway disease that
occurs in response to allergen exposure. The disease is
characterized by T-helper 2 (Th2) cell-dominated airway
inflammation and airway hyper-responsiveness. The
house dust mite is considered the most important in-
door allergen affecting the development of asthma [1,2],
and Dermatophagoides pteronyssinus is the predominant
species of dust mite in Taiwan [3]. The 14-kD group 2
allergen isolated from Dermatophagoides pteronyssinus* Correspondence: chchen1@dragon.nchu.edu.tw
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reproduction in any medium, provided the or(Dp2) is considered a major allergen related to allergic
asthma because the recombinant protein reacts with IgE
in sera from 80% of mite-allergic patients [4].
Allergen-specific immunotherapy has been demon-
strated to have therapeutic potential for the treatment of
allergic asthma in many animal and clinical studies. The
mechanism is related to a change in the immune response
as a result of repeated allergen exposure. It has been dem-
onstrated that immunotherapy induces T-helper 1 (Th1)
cell differentiation in addition to down-regulating the Th2
cascade, and other studies have shown that regulatory T
(Treg) cells play an important role in immunotherapy
[5,6]. Subcutaneous injection immunotherapy (SCIT) has
been shown to reduce the likelihood of developing asthma
in both adults and children with rhinitis [7,8]. However,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as anaphylactic reactions and the acceptability of injec-
tions [9]. Sublingual immunotherapy (SLIT), the adminis-
tration of an allergen via the oral mucosa, has also been
confirmed to reduce the incidence of new asthma cases
[10]. The lower frequency of side effects and the relative
convenience make SLIT a more acceptable treatment for
children [11].
The human gastrointestinal tract is exposed to numer-
ous dietary proteins, most of which are tolerated through
suppression of the immune response in a process known
as oral tolerance. Data from animal studies and early-
phase clinical trials suggest that oral immunotherapy with
an allergen is able to effectively induce tolerance and pre-
vent food allergies [12]. To date, the effect of oral im-
munotherapy with allergens on the development of
asthma has not been clearly identified.
Because the purification of Dp2 from dust mites is dif-
ficult, recombinant DNA techniques have been used to
study allergen-specific immunotherapy [13,14]. Further-
more, our previous studies demonstrated that the mam-
mary gland of transgenic mice can serve as a bioreactor
to produce recombinant protein in the milk [15,16]. We
therefore investigated transgenic mice expressing recom-
binant Dp2 in their milk. We hypothesized that the oral
administration of transgenic Dp2-containing milk could
induce tolerance and prevent allergic airway inflamma-
tion in a validated murine model of allergic asthma.
Methods
Construction of the αLA-CN-Dp2 transgene and
production of transgenic mice
The αLA-CN/pCR3 vector, which is a mouse mammary
gland-specific expression vector, was used for transgene
construction as previously described [15]. The 0.6 kb
cloned Dp2 cDNA (GenBank accession number:
AF276239) in the pGEM7 plasmid was used to generate
a mature Dp2 coding sequence by PCR amplification
using the primer set of Dp2-HpaI(+) (5′-CGTTAA
CTCGTGATCAAGTCGAT-3′) and Dp2-XhoI(−) (5′-
ACTCGAGGGTTTTCCCAGTCA-3′). The amplified
products were double digested with HpaI and XhoI (cut-
ting sites are underlined in the above primer sequences)
and then ligated into the αLA-CN/pCR3 vector. The 3.1
kb transgene fragment, consisting of the α-lactalbumin
(αLA) promoter (2.0 kb), the αS1-casein (CN) signal
peptide leader sequence (15-amino acids), the signal
peptide-truncated Dp2 cDNA (Dp2t; 0.6 kb), and the bo-
vine growth hormone (bGH) polyadenylation signal se-
quence (0.5 kb), was obtained from the αLA-CN-Dp2t/
pCR3 vector with double digestion with BamHI and
BbsI (Figure 1A). The transgene DNA was purified by
CsCl2 gradient ultra-centrifugation, and transgenic CD-
1 mice were generated by pronuclear microinjection asdescribed previously [16,17]. The animal trials in this
study were approved by the Institutional Animal Care
and Use Committee of National Chung Hsing Univer-
sity, Taiwan (IACUC No.98-52).Detection of the transgene by PCR screening and
Southern blot hybridization
Tail DNA from the founder mice was used to screen
for the αLA-CN-Dp2t transgene by PCR amplification.
PCR was performed using a set of primers, αLA-124(+)
(5′-CTCTCTTGTCATCCTCTTCC-3′) and Dp2-395(−)
(5′-CCAAAACACCATCATCACCC-3′), that amplified
a 520 bp αLA-CN-Dp2t fusion gene. PCR was
performed with 35 cycles of denaturation at 94°C for 30
sec, annealing at 55°C for 30 sec, and extension at 72°C
for 45 sec in a thermal cycler (AG-9600; AcuGen sys-
tems, Lowell, MA). The PCR products were analyzed on
a 1.5% agarose gel and detected by ultraviolet transillu-
mination. The screening results were further confirmed
by Southern blot hybridization as described previously
[18]. Briefly, ten micrograms of genomic DNA was
digested with StuI at 37°C overnight, electrophoresed on
a 0.8% agarose gel, and transferred to a Durose nitrocel-
lulose membrane (Stratagene, La Jolla, CA). The HpaI-
XhoI fragment of the Dp2 cDNA (0.6 kb) was used as a
radioactive probe and hybridized to the membrane.
Blots were subjected to autoradiography for one week at
−20°C.Detection of recombinant Dp2 expression in the milk of
transgenic mice
To identify the expression of recombinant Dp2 in the
milk, the lactating female progeny of the transgenic mice
were injected with oxytocin (China Chemical & Pharma-
ceutical Co., Ltd, Taipei, Taiwan), and milk was collected
under anesthesia. Ten-fold dilutions of the milk samples
collected during the different lactation stages were
subjected to 12% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and stained with Coomassie blue. Milk
proteins were electrotransferred from the gel to a PVDF
membrane (MEN Life Science Products, Boston, MA).
The expression of recombinant Dp2 was detected with a
rabbit anti-Dp2 antibody (1:2000 dilution) and an anti-
rabbit IgG second antibody conjugated with horseradish
peroxidase (HRP) (1:10000 dilution). The blots were
then visualized with the chemiluminescent ECLTM de-
tection system (Amersham, UK) and exposed to X-ray
film [18]. The levels of recombinant Dp2 in different lac-
tating stages were quantified using an enzyme-linked im-
munosorbent assay (ELISA). A standard curve using
purified Dp2 (Indoor Biotech. Ltd., UK) diluted from
5 mg/mL to 156.25 μg/mL was used to estimate the
amount of recombinant Dp2 in the milk.
Figure 1 Schematic map of the αLA-CN-Dp2t transgene construct and detection of its integration into transgenic mice. (A) The structure
of the αLA-CN-Dp2t-bGHpoly(A) fusion gene is shown. The construct includes the mammary gland-specific αLA promoter, the αS1-casein (CN)
signal peptide leader sequence, the Dermatophagoides pteronyssinus mite truncated Dp2 (Dp2-t) cDNA, and the bovine growth hormone gene
polyA signal. This construct was digested with BamHI and BbsI for microinjection. A primer pair for PCR screening was designed to flank the
junction of the 3′-end of the αLA promoter and the 5′-end of the Dp2t cDNA. (B) Transgenic founder mice were identified through PCR
screening. Mr. represents a DNA size marker of the 100-bp leader. (C) Southern blots showing the integration patterns of the transgene in the
transgenic mice. PC represents pCR-αLA-CN-Dp2t plasmid DNA (positive control). NC represents normal mouse DNA (negative control).
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Freshly dissected mammary glands from transgenic and
wild-type mice in the D15 lactating stage were fixed
in paraformaldehyde as described [19]. Tissue sections
(5 μm) were stained with hematoxylin and eosin (H&E)
and photographed under a light microscope (Carl
Zeiss, Germany). Immunohistochemical analysis was
conducted as described [20,21]. Briefly, the Dp2 poly-
clonal antibody (LifeSpan BioSciences Inc., Seattle, WA,
USA) was diluted 1:20 in 1% bovine serum albumin
(BSA) in phosphate buffered saline (PBS), and 50 μl ali-
quots of anti-Dp2 were incubated with the tissue sec-
tions for 30 min at 37°C. After washing with 10 volumes
of BSA-PBS buffer, the mammary gland slides were incu-
bated with goat anti-rabbit IgG antibody conjugated with
fluorescein isothiocyanate (FITC; Boehringer-Mannheim,
Germany) at a dilution of 1:100 for 30 min at 37°C. After
washing, the slides were observed under a NikonOptiphot microscope (Nikon, Tokyo, Japan) equipped
with epifluorescence optics.
An animal model of allergic airway inflammation
The Dp2-containing milk was collected from different fe-
males of line #10 offspring, then pooled and quantified.
The Dp2 concentration was adjusted to 2.0 mg/mL be-
fore feeding. Three-week-old CD-1 mice were obtained
from the animal breeding center of the College of Medi-
cine, National Taiwan University (the strain originated
from the Jackson Laboratory, Bar Harbor, ME). These
mice were divided into 3 experimental groups. (1) Group
A: unsensitized mice fed wild-type (WT) milk (3.0 mL/kg
body weight/day), which served as the normal control
group. These mice were fed normal milk collected from
WT mice and did not receive the subsequent
sensitization with Dp2. (2) Group B: sensitized mice fed
transgenic Dp2 milk (adjusted to 2.0 mg/mL Dp2 in the
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milk collected from transgenic mice for 4 weeks and
were then sensitized with an intraperitoneal injection of
Dp2. (3) Group C: sensitized mice fed WT milk (3.0 mL/
kg body weight/day). These mice were fed normal milk
collected from wild-type mice and were then sensitized
with Dp2. The sensitization was performed twice by in-
traperitoneal injection of 10 μg of purified Dp2 (Indoor
Biotech. Ltd.) emulsified in 4 mg of Al(OH)3 on days 29
and 43. Al(OH)3 served as an adjuvant for induction of a
good Th2 response. To induce allergic airway inflamma-
tion, the three groups of mice were challenged by expos-
ure to an aerosol of 0.1% Dp2 for 30 min on day 50. All
of the animal trails were repeated in two independent
cohorts.
Histopathological examination of lung alveoli tissues
After sacrificing the mice, the left lobes of the lung were
dissected and inflated with 0.6 mL of 10% formalin for
histological study. Paraffin sections prepared from the
lungs were stained with hematoxylin and eosin for evalu-
ation. We assessed the degree of alveolar congestion,
hemorrhage, leukocyte infiltration, and the thickness of
the alveolar wall [19].
Analysis of pulmonary function
Eighteen hours after the aerosol challenge, mice were
placed into a barometric plethysmograph (Buxco Elec-
tronics, Troy, NY) to measure their pulmonary function.
Airway hyper-responsiveness was determined by meas-
uring the Penh values (enhanced pause) when mice were
exposed to an increasing dose of nebulized methacholine
(Mch), as previously described [18,22]. The Penh values
were calculated as the means ± SEM.
Analysis of airway inflammation and cytokine expression
After the pulmonary function measurements were
preformed, the experimental mice were sacrificed for the
collection of bronchoalveolar lavage (BAL) fluid and
lung sections. BAL fluid was collected using 500 μL of
sterile endotoxin-free saline to wash the lungs. BAL cells
were diluted in 1 mL PBS after centrifugation at 500 g at
4°C. The percentage of leukocytes among the BAL cells
was determined with a hemocytometer. The cytospin
preparation of 100 μL of BAL fluid was followed by
staining with Liu stain [23] for total cell counts. The dif-
ferential counts of BAL cells were performed under a
microscope, and 200 total cells were counted. In
addition, the supernatant of the BAL fluid was aspirated
and stored at −80°C until the cytokine levels were assayed.
The IL-4 and IFN-γ levels in the BAL fluid were deter-
mined using commercial ELISA kits according to the
manufacturer’s instructions (BD Biosciences Pharmingen,
San Diego, CA) [19].Determination of Dp2-specific IgE
Blood was collected from the tail vein of mice before
sacrifice. The serum Dp2-specific IgE levels were deter-
mined using an ELISA kit. The plates were coated with
200 μL of purified Dp2 overnight at a concentration of
10 μg/mL in a 4°C refrigerator. After the sample serum
was incubated with the plate for 2 h, a biotin-conjugated
goat anti-mouse IgE detection antibody was added. The
bound enzyme substrate was detected with streptavidin-
alkaline phosphatase and p-nitrophenylphosphate (pNPP,
Sigma, St. Louis, MO). After the chemical reaction, the
optical density of the sample was measured at 405 nm in
a multiscan spectrophotometer (BioRad, Hercules, CA).
Statistical analysis
To assess the changes in the cell counts in the BAL fluid,
in the cytokine contents, in the IgE levels, and in the level
of airway hyper-responsiveness, repeated measures
ANOVA was performed to compare the groups. Following
ANOVA, the Duncan multiple range test was used to iden-
tify differences between the sensitized mice fed transgenic
Dp2 milk and the sensitized mice fed WT milk. A value of
P < 0.05 was used to indicate statistical significance.
Results
Generation of transgenic mice carrying the αLA-CN-Dp2
fusion gene
To generate transgenic mice capable of expressing re-
combinant Dp2 in their mammary glands, a DNA con-
struct that carried a 2.0 kb regulatory sequence for the
bovine-lactalbumin gene and the cDNA for a 0.6 kb ma-
ture Dp2 peptide with a leading αS1-CN signal sequence
(15 amino acids) was engineered in the cloning vector
pCR3 (Figure 1A). For pronuclear embryo microinjec-
tion, the mammary gland-specific cassette of the αLA-
CN-Dp2t-bGHpolyA construct was excised from the
vector by double digestion with BamHI and BbsI.
The microinjected embryos were transferred into the fal-
lopian tubes of pseudopregnant mice. Six of the twenty-
two newborn mice displayed a 520 bp PCR product
indicative of positive transgenic mice (Figure 1B).
The number of integration sites in these transgenic
mice was analyzed by Southern blotting using StuI re-
striction enzyme digestion, which was used to cut the
transgene-cellular junction. The results (Figure 1C)
showed that the number of integration sites varied from
one (Tg-#8 and Tg-#16) to three (Tg-#3 and Tg-#10).
Successful expression of recombinant Dp2 in the milk of
transgenic mice
To analyze recombinant Dp2 expression in the trans-
genic mice, immunohistochemical (IHC) staining was
performed on mammary gland sections. Data showed
that recombinant Dp2 accumulated to high levels within
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bules during the D15 lactating stage in Tg-#10 trans-
genic female offspring (Figure 2A, upper right panel).Figure 2 Recombinant Dp2 expression in the transgenic mammary gl
from Dp2-transgenic and wild type mice in the D15 lactating stage were fi
antibodies for immunohistochemical (IHC; right panel) analysis. The structu
tissues and ‘LT’ for lactiferous tubules or secretary tubules. Samples were vi
100X). (B) Milk from transgenic female mice was collected, centrifuged, and
recombinant Dp2 protein was detected in this milk by Western blot analys
transgenic milk that was collected from transgenic mice on 7th day of lact
collected during the middle lactation stage. D28 represents the transgenic
molecular-weight protein marker. PC represents the sample containing wat
mice. (C) Quantification of the amounts of recombinant Dp2 protein in theThere were no detectable FITC signals or only a
few green fluorescent background signals in the sections
of mammary glands from lactating wild-type miceand and secretion in milk. (A) Freshly dissected mammary glands
xed and stained with hematoxylin and eosin (H&E; left panel) and with
res of the mammary gland are labeled as ‘MA’ for mammary acini
ewed using an epifluorescence microscope (original magnification,
subjected to SDS-PAGE (upper panel). The expression of the
is using a rabbit anti-Dp2 antibody (lower panel). D7 represents the
ation (early stage). D14 and D21 represent the transgenic milk
milk collected during the late lactation stage. Mr. represents a low-
er and purified Dp2. NC represents the milk collected from wild-type
transgenic milk samples collected during different stages of lactation.
Figure 3 Experimental protocol. Transgenic Dp2 milk and wild-
type (WT) milk were collected and fed to 3-week-old pups for 28
days. Mice were divided into three experimental groups. Two of the
three groups of mice were sensitized by intraperitoneal injection of
10 μg of purified Dp2 on days 29 and 43. All mice were then
challenged with 0.1% Dp2 aerosols on day 50. Mice underwent
pulmonary function testing 18 h after aerosol challenge. BAL fluid,
serum, and lung sections were collected on day 51 for analysis of
the level of airway inflammation.
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of Dp2 secretion, milk was collected from lactating fe-
males of transgenic mice (Tg-#10) and wild-type control
mice (NC) for SDS-PAGE (Figure 2B, upper panel) and
Western blot (Figure 2B, lower panel) analyses. The
assays were performed on milk samples collected in
the early (Day 7), middle (Days 14 and 21), and late
(Day 28) stages of lactation. The results showed that
recombinant Dp2 was successfully expressed and se-
creted in the milk of the transgenic mice (Figure 2B).
The transgenic milk collected during the middle lacta-
tion stage (Day 21) had the highest expression of
recombinant Dp2 protein, with a concentration of
2.75 ± 0.21 mg/mL detected by ELISA (Figure 2C).
Among four transgenic lines analyzed, the Tg-#10
line exhibited the highest Dp2 expression level. It
contained three copies of the Dp2 transgene and stable
germline transmission was demonstrated in offspring
by slot-blot hybridization (Additional file 1). This
transgenic mouse line was selected to breed offspring
for further milk collection.
To characterize the tissue-specific expression of Dp2
mRNA transcripts, total tissue RNAs were extracted
from different organs of transgenic lactating females. As
shown in the Additional file 2, the Dp2 transcript, a 310
bp RT-PCR product, was found in the mammary gland
(Ma) of lactating transgenic mice. No homologous tran-
scripts were detectable in the brain (Br), heart (He), lung
(Lu), liver (Li), spleen (Sp), kidney (Ki), ovary (Ov),
muscle (Mu), or wild-type mouse mammary gland (NC-
Ma). The results show that the Dp2 allergen was only
expressed in the lactating mammary gland with no leaky
expression in other tissues.
Effect of transgenic Dp2 milk on airway
hyper-responsiveness
The timeline of the animal trail to test whether the oral ad-
ministration of transgenic animal milk containing the Dp2
allergen can down-regulate allergen-specific airway hyper-
responsiveness and inflammation is shown in Figure 3. The
levels of airway hyper-responsiveness in the three ex-
perimental groups were measured 18 h after Dp2 aero-
sol challenge. Sensitized mice fed WT milk (Group C)
had higher Penh values than unsensitized mice (Group
A) when mice were exposed to an increasing dose (10–
100 mg/mL) of nebulized methacholine (P < 0.01). Thus,
sensitized mice fed WT milk had increased airway
hyper-responsiveness. In sensitized mice fed transgenic
Dp2 milk (Group B), the Penh values were significantly
reduced compared with the values in sensitized mice
fed WT milk (P < 0.05; Figure 4). The results suggested
that pre-treatment with transgenic Dp2 milk can reduce
airway hyper-responsiveness in mice upon Dp2-induced
allergic airway inflammation.Suppression of Dp2-induced airway inflammation by the
ingestion of Dp2 milk
Inflammatory cell infiltration and epithelium damage in the
lung alveoli tissues were examined by histochemical stain-
ing and compared among different experimental groups
after Dp2 allergic challenge. We observed reductions in al-
veolar congestion, hemorrhage, leukocyte infiltration, and
the thickness of the alveolar wall in the sensitized mice fed
transgenic Dp2 milk (Group B; Figure 5B) compared with
the sensitized mice fed WT milk (Group C; Figure 5C).
The leukocyte subpopulations in the BAL fluids were
measured to evaluate the effect of pre-treatment with
transgenic Dp2 milk. The results showed that sensitized
mice fed transgenic Dp2 milk (Group B) had significantly
fewer total lung infiltrated cells (P < 0.01), in their BAL
fluid than sensitized mice fed WT milk (Group C), as
demonstrated by the cytospin images in Figure 6A and the
quantitative total infiltrated cell population counts in Fig-
ure 6B. In addition, significantly lower percentages of neu-
trophils (P < 0.05) and eosinophils (P < 0.05) were
observed in the BAL fluids of Dp2 milk-treated mice com-
pared with WT milk-treated mice (Additional file 3).
Effect of transgenic Dp2 milk on bronchoalveolar lavage
fluid cytokine levels
The levels of IL-4 (a Th2 cytokine) and INF-γ (a Th1
cytokine) were measured in the BAL fluid. Sensitized
Figure 4 The effect of transgenic Dp2 milk on airway hyper-
responsiveness. Individual mice were subjected to barometric
whole-body plethysmography, and the enhanced pause (Penh)
values were measured in response to challenge with different doses
of nebulized methacholine (Mch). The data are presented as the
means ± SEM. n = 5 mice per group with two independent
experiments. * indicates P < 0.05 and ** indicates P < 0.01 for
unsensitized mice compared with sensitized mice fed WT milk or
Dp2 milk; # indicates P < 0.05 for sensitized mice fed transgenic Dp2
milk compared with sensitized mice fed WT milk.
Figure 5 Histopathological sections of lung tissues. Lung alveoli
with 100X magnification. (A) Group A: Unsensitized mice fed WT milk as
the normal control group; (B) Group B: Sensitized mice fed transgenic
Dp2 milk as the immunotherapy group; (C) Group C: Sensitized mice
fed WT milk as the allergic airway inflammation group.
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lower IL-4 levels than sensitized mice fed WT milk
(0.537 ± 0.06 pg/mL vs. 1.734 ± 0.157 pg/mL; P < 0.01)
(Figure 7A). We also observed a significant difference in
IFN-γ levels between sensitized mice fed transgenic Dp2
milk and sensitized mice fed WT milk (1.572 ± 0.213 pg/
mL vs. 1.046 ± 0.229 pg/mL; P < 0.05) (Figure 7B). These
results demonstrate that pre-treatment with transgenic
Dp2 milk not only suppressed the expression of Th2 cyto-
kines but also attenuated the infiltration of inflammatory
cells in the lungs of mice that were sensitized and chal-
lenged with the Dp2 dust mite allergen. Lung sections also
showed attenuated inflammatory cell infiltration in both
the lung parenchyma and the bronchus of sensitized mice
fed recombinant Dp2 milk compared with sensitized mice
fed WT milk (data not shown).
Effect of transgenic milk on Dp2-specific IgE in the serum
The levels of Dp2-specific IgE in the sera of mice were
measured by ELISA. The results showed that sensitized
mice fed transgenic Dp2 milk (Group B, 0.257 ± 0.015 pg/
mL) had lower serum IgE levels than sensitized mice fed
WT milk (Group C, 0.717 ± 0.017 pg/mL; P < 0.01) and
unsensitized normal mice (Group A, 0.443 ± 0.021 pg/mL;
P < 0.05) (Figure 7C). These data demonstrate that mice
given transgenic Dp2 milk had decreased IgE levels in the
serum after sensitization and challenge with Dp2.
Discussion
In this study, we engineered transgenic mice to express
a recombinant Dp2 peptide and secrete it in their milk.
The ingestion of this transgenic Dp2-containing milkattenuated Th2 responses in mice that were subse-
quently sensitized and challenged with purified Dp2
antigen. Both allergen-induced airway inflammation and
airway hyper-responsiveness were decreased in sensi-
tized mice fed transgenic Dp2 milk compared to sensi-
tized mice fed WT milk. The immunomodulatory effect
of transgenic Dp2 milk ingestion was associated with a
decrease in IL-4 levels and an increase in IFN-γ levels.
These findings suggest that the effect of pretreatment
with transgenic Dp2 milk might be related to the down-
Figure 6 Cytospin images of infiltrated cell types in the bronchoalveolar lavage (BAL) fluid of mice by Liu’s stain. (A) Unsensitized mice
fed WT milk as the normal control group. (B) Sensitized mice fed transgenic Dp2 milk as the immunotherapy group. (C) Sensitized mice fed WT
milk as the allergic airway inflammation group. The images were observed under 100X (upper panels) or 400X (lower panels) magnifications. E:
eosinophils; L: lymphocytes; M: macrophages; N: neutrophils. (D) Total infiltrated cell counts in BAL fluids from the three experimental gruops.
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Th1 response when these mice received a subsequent al-
lergen sensitization and challenge. A limitation of our
study is that the therapeutic intervention (the adminis-
tration of transgenic Dp2 milk) occurred prior to intra-
peritoneal of the mice. It remains to be determined
whether the ingestion of transgenic Dp2 milk could have
an immunomodulatory effect on mice with established
allergic airway inflammation.
Evidence from a previous animal study suggests that
ovalbumin (OVA) antigen transfer through breast milk
can induce immune tolerance and prevent allergic
asthma [24]. The authors found that OVA antigen was
efficiently transferred from the mother’s milk to neonatal
mice, and the induction of tolerance relied on the pres-
ence of the allergen itself in the milk. This finding is
in agreement with the immunomodulatory effect in
our model of transgenic Dp2 milk ingestion. In our
study, allergen expression in recombinant milk wasdemonstrated through IHC staining and Western blot
analyses (Figure 2). The Dp2-containing milk produced
by transgenic mice is convenient for breast feeding the
newborns, but the milk uptake volume and Dp2 dosage
are not easy to measure. Therefore, weaning age (three-
week old) pups were used in this study so that we could
carefully control the dose of orally ingested Dp2 doses.
Furthermore, transgenic Dp2 milk was demonstrated to
protect against allergic airway inflammation in this mur-
ine model of allergic asthma. In another study by Hsu
et al. [25], Zucchini yellow mosaic virus (ZYMV) was
used as a vector to express a dust mite Dp5 allergen in
squash plants. The ingestion of an extract of this plant
by mice previously sensitized to that allergen inhibited
allergic airway inflammation and specific IgE synthesis.
Our study was also based on the concept of producing a
large amount of recombinant Dp2 allergen in a manage-
able genetically engineered system. However, in our
study, the transgenic product was administered to mice
Figure 7 Immunomodulatory effects of transgenic Dp2 milk on the
expression of cytokines and allergen-specific immunoglobulins. The
supernatant of the BAL fluid from mice in the three experimental
groups was analyzed by ELISA to determine the IL-4 (A) and IFN-γ
(B) levels. Serum samples from mice in the three experimental
groups were analyzed to determine the Dp2-specific IgE (C) by
ELISA. The data are expressed as the means ± SD of values obtained
for individual mice. n = 5 mice per group. (* P < 0.05; ** P < 0.01)
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that differs from that used in the previous study [25].
The results of our study suggest that pre-treatment with
transgenic Dp2 milk can down-regulate allergic airway
inflammation. TGF-β and immunoglobulins in breast
milk are thought to be important immunomodulatory
factors affecting tolerance induction in neonates [24,26].
Further studies are needed to determine whether theseimmunomodulatory factors are important in the trans-
genic Dp2 milk.
The sensitized mice fed transgenic Dp2 milk still had
inflammatory cell infiltration in the lung sections and in-
creased airway hyper-responsiveness when compared
with unsensitized normal mice. Therefore, the ingestion
of transgenic Dp2 milk could induce a partial protective
effect in mice. Mosconi et al. [27] showed that antigen-
binding maternal IgG complexes in breast milk are more
potent inducers of tolerance and prevention of asthma.
The expression of TGF-β in breast milk has been dem-
onstrated to be an important tolerogenic factor in toler-
ance induction [24,26]. It has been demonstrated that
Th1 adjuvants, such as monophosphoryl lipid A and the
immunostimulatory CpG motif in DNA, can enhance
the effects of allergen-specific immunotherapies [28-30].
Further studies could attempt to enhance the protective
effect of transgenic Dp2 milk by combining it with im-
munomodulatory factors or Th1 adjuvants.
The development of biotechnology that allows trans-
gene expression in milk-producing animals has opened
up new strategies to produce large amounts of a given
recombinant protein in milk. The advantages of mam-
mary glands as bioreactors are the higher production
capability and the greater flexibility relative to other pro-
duction systems [31,32]. Milk-secreted proteins are usually
in the bio-active form as a result of proper posttransla-
tional modifications, and these proteins can be easily
purified for therapeutic use. Among the well-known re-
combinant proteins are human insulin-like growth factor
1 (IGF-1) [33], human growth hormone (GH) [34], recom-
binant tissue plasminogen activator (tPA) [35], human im-
munoglobulin [36], and human lactoferrin (hLF) [37].
Recombinant antithrombin (ATryn), the first pharmaceut-
ical protein made from the milk of transgenic goats, has
been approved by the European community and the U.S.
Food and Drug Administration (FDA) for people with her-
editary antithrombin deficiency [38]. The ingestion of
transgenic Dp2 milk from dairy animals such as transgenic
goats and cows would be a convenient and acceptable
route of human administration. Our study demonstrated
that the oral administration of transgenic Dp2 milk could
be a feasible way to protect people from the development
of allergic asthma.Conclusions
In summary, we have successfully produced transgenic
mice expressing recombinant Dp2 peptide in their milk.
Pre-treatment of mice with transgenic Dp2 milk can par-
tially protect mice from allergen-induced airway inflam-
mation and hyper-responsiveness. Our study may pave
the way for designing new strategies to prevent allergic
asthma in humans.
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Additional file 1: Determination of Dp2 transgene copies in the
genomes of transgenic (line Tg-#10) founder (F0) and its offspring
(F1) by slot-blot hybridization. (A) Ten micrograms of genomic DNA
were blotted onto a nitrocellulose membrane and hybridized with a 0.6
kb Dp2 probe. (B) The filter was stripped and rehybridized with a 0.8 kb
probe from the mouse β-actin gene that was used as an internal control.
Copy standards (Std) were prepared by mixing 10 μg of non-transgenic
tail DNA with a known amount of transgene plasmid DNA to produce
transgene copy standards as shown in lane Std.
Additional file 2: Tissue-specific expression of the Dp2 transgene
detected by RT-PCR. Tissues were removed from lactating transgenic
females at Day 14. Total RNA was isolated from mammary gland (Ma),
brain (Br), heart (He), lung (Lu), liver (Li), spleen (Sp), kidney (Ki), ovary
(Ov), muscle (Mu), and wild-type mouse mammary glands (NC-Ma). A
non-lactation stage of mammary gland (dry) was used as a negative
control. PC: positive control from αLA-CN-Dp2t plasmid DNA. The
efficiency of DNase I treatment to eliminate DNA contamination was
determined using total RNA from a transgenic mammary gland (tMa).
When the reverse transcriptase was omitted from the reaction, no
amplification was observed. A β-actin primer set was used as an internal
control. Mr.: 100-bp ladder of DNA size marker.
Additional file 3: Differential cell counts in the bronchoalveolar
lavage (BAL) fluid. The percentages of eosinophils, neutrophils,
lymphocytes, and macrophages in the BAL fluid were calaulated based
on a total of 200 cells counted per slide using cytospin preparations
stained with Liu’s stain. The data are presented as the means ± SD of
values obtained from two independent experiments. n = 5 in each group.
(* P <0.05).
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